Jan 16 (Reuters) - Redhill Biopharma Ltd:
* REDHILL BIOPHARMA ANNOUNCES FINAL RESULTS FROM PHASE II STUDY WITH BEKINDAÂ® FOR IBS-D
* REDHILL BIOPHARMA - INDEPENDENT REVIEW & ANALYSIS OF FINAL RESULTS CONFIRMED THAT PHASE II STUDY WITH BEKINDA 12 MG SUCCESSFULLY MET PRIMARY ENDPOINT
* REDHILL BIOPHARMA - PLANS TO MEET WITH FDA IN H1 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:
 